1183-35-3 Usage
Description
DIHYDROOUABAIN, a cardiac glycoside, is a naturally occurring compound derived from the foxglove plant. It possesses potent biological activities and is known for its ability to modulate the sodium-potassium pump, which plays a crucial role in maintaining the balance of electrolytes in cells. This unique property of DIHYDROOUABAIN has led to its exploration as a potential therapeutic agent in various medical applications.
Uses
Used in Anticancer Applications:
DIHYDROOUABAIN is used as an anticancer agent for its ability to target various cancer cells. It has been found to be effective against a range of malignancies, including solid tumors and leukemia. The compound's mechanism of action involves disrupting the sodium-potassium pump, which can lead to the inhibition of cancer cell growth and the induction of apoptosis. Additionally, DIHYDROOUABAIN has shown potential in enhancing the efficacy of conventional chemotherapy by increasing chemo-sensitivity in drug-resistant cancer cells.
Used in Cardiac Applications:
DIHYDROOUABAIN is used as an inotropic drug for its ability to strengthen the contractions of the heart muscle. This application is particularly relevant in the treatment of heart failure, where the heart's ability to pump blood effectively is compromised. By modulating the sodium-potassium pump, DIHYDROOUABAIN can improve cardiac function and overall cardiovascular health.
Used in Drug Delivery Systems:
To overcome potential limitations and enhance the therapeutic potential of DIHYDROOUABAIN, researchers have developed novel drug delivery systems. These systems aim to improve the bioavailability, targeting, and overall efficacy of the compound in treating various medical conditions, including cancer and heart diseases. Utilizing advanced nanotechnology and other innovative approaches, these drug delivery systems can help maximize the benefits of DIHYDROOUABAIN while minimizing potential side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1183-35-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,1,8 and 3 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1183-35:
(6*1)+(5*1)+(4*8)+(3*3)+(2*3)+(1*5)=63
63 % 10 = 3
So 1183-35-3 is a valid CAS Registry Number.
InChI:InChI=1/C29H46O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h13-19,21-25,30-32,34-38H,3-12H2,1-2H3/t13-,14?,15-,16+,17?,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
1183-35-3Relevant articles and documents
Cardiac glycoside activities link Na+/K+ ATPase ion-transport to breast cancer cell migration via correlative SAR
Magpusao, Anniefer N.,Omolloh, George,Johnson, Joshua,Gascn, Jos,Peczuh, Mark W.,Fenteany, Gabriel
, p. 561 - 569 (2015)
The cardiac glycosides ouabain and digitoxin, established Na+/K+ ATPase inhibitors, were found to inhibit MDA-MB-231 breast cancer cell migration through an unbiased chemical genetics screen for cell motility. The Na+/K+ ATPase acts both as an ion-transporter and as a receptor for cardiac glycosides. To delineate which function is related to breast cancer cell migration, structure-activity relationship (SAR) profiles of cardiac glycosides were established at the cellular (cell migration inhibition), molecular (Na+/K+ ATPase inhibition), and atomic (computational docking) levels. The SAR of cardiac glycosides and their analogs revealed a similar profile, a decrease in potency when the parent cardiac glycoside structure was modified, for each activity investigated. Since assays were done at the cellular, molecular, and atomic levels, correlation of SAR profiles across these multiple assays established links between cellular activity and specific protein-small molecule interactions. The observed antimigratory effects in breast cancer cells are directly related to the inhibition of Na+/K+ transport. Specifically, the orientation of cardiac glycosides at the putative cation permeation path formed by transmembrane helices αM1-M6 correlates with the Na+ pump activity and cell migration. Other Na+/K+ ATPase inhibitors that are structurally distinct from cardiac glycosides also exhibit antimigratory activity, corroborating the conclusion that the antiport function of Na+/K+ ATPase and not the receptor function is important for supporting the motility of MDA-MB-231 breast cancer cells. Correlative SAR can establish new relationships between specific biochemical functions and higher-level cellular processes, particularly for proteins with multiple functions and small molecules with unknown or various modes of action.
